326 related articles for article (PubMed ID: 20696774)
1. Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target.
Desai MK; Mastrangelo MA; Ryan DA; Sudol KL; Narrow WC; Bowers WJ
Am J Pathol; 2010 Sep; 177(3):1422-35. PubMed ID: 20696774
[TBL] [Abstract][Full Text] [Related]
2. An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction.
Desai MK; Guercio BJ; Narrow WC; Bowers WJ
Glia; 2011 Apr; 59(4):627-40. PubMed ID: 21294162
[TBL] [Abstract][Full Text] [Related]
3. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology.
Desai MK; Sudol KL; Janelsins MC; Mastrangelo MA; Frazer ME; Bowers WJ
Glia; 2009 Jan; 57(1):54-65. PubMed ID: 18661556
[TBL] [Abstract][Full Text] [Related]
4. Alterations of myelin morphology and oligodendrocyte development in early stage of Alzheimer's disease mouse model.
Wu Y; Ma Y; Liu Z; Geng Q; Chen Z; Zhang Y
Neurosci Lett; 2017 Mar; 642():102-106. PubMed ID: 28174059
[TBL] [Abstract][Full Text] [Related]
5. Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer's disease.
Vanzulli I; Papanikolaou M; De-La-Rocha IC; Pieropan F; Rivera AD; Gomez-Nicola D; Verkhratsky A; Rodríguez JJ; Butt AM
Neurobiol Aging; 2020 Oct; 94():130-139. PubMed ID: 32619874
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men.
Behrendt G; Baer K; Buffo A; Curtis MA; Faull RL; Rees MI; Götz M; Dimou L
Glia; 2013 Feb; 61(2):273-86. PubMed ID: 23090919
[TBL] [Abstract][Full Text] [Related]
7. Retinoid X receptor activation promotes re-myelination in a very old triple transgenic mouse model of Alzheimer's disease.
Santos-Gil DF; Arboleda G; Sandoval-Hernández AG
Neurosci Lett; 2021 Apr; 750():135764. PubMed ID: 33621639
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia.
Nguyen TV; Hayes M; Zbesko JC; Frye JB; Congrove NR; Belichenko NP; McKay BS; Longo FM; Doyle KP
Acta Neuropathol Commun; 2018 Sep; 6(1):100. PubMed ID: 30249297
[TBL] [Abstract][Full Text] [Related]
9. Oligodendrocytes and Alzheimer's disease.
Cai Z; Xiao M
Int J Neurosci; 2016; 126(2):97-104. PubMed ID: 26000818
[TBL] [Abstract][Full Text] [Related]
10. Progressive white matter pathology in the spinal cord of transgenic mice expressing mutant (P301L) human tau.
Lin WL; Zehr C; Lewis J; Hutton M; Yen SH; Dickson DW
J Neurocytol; 2005 Dec; 34(6):397-410. PubMed ID: 16902761
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound with microbubbles improves memory, ameliorates pathology and modulates hippocampal proteomic changes in a triple transgenic mouse model of Alzheimer's disease.
Shen Y; Hua L; Yeh CK; Shen L; Ying M; Zhang Z; Liu G; Li S; Chen S; Chen X; Yang X
Theranostics; 2020; 10(25):11794-11819. PubMed ID: 33052247
[TBL] [Abstract][Full Text] [Related]
12. Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex.
Welikovitch LA; Do Carmo S; Maglóczky Z; Szocsics P; Lőke J; Freund T; Cuello AC
Acta Neuropathol; 2018 Dec; 136(6):901-917. PubMed ID: 30362029
[TBL] [Abstract][Full Text] [Related]
13. Amyloidosis is associated with thicker myelin and increased oligodendrogenesis in the adult mouse brain.
Ferreira S; Pitman KA; Wang S; Summers BS; Bye N; Young KM; Cullen CL
J Neurosci Res; 2020 Oct; 98(10):1905-1932. PubMed ID: 32557778
[TBL] [Abstract][Full Text] [Related]
14. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
15. Identification of Tau protein as a novel marker for maturation and pathological changes of oligodendrocytes.
Torii T; Miyamoto Y; Nakata R; Higashi Y; Shinmyo Y; Kawasaki H; Miyasaka T; Misonou H
Glia; 2023 Apr; 71(4):1002-1017. PubMed ID: 36565228
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
[TBL] [Abstract][Full Text] [Related]
17. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
18. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
19. Focal demyelination in Alzheimer's disease and transgenic mouse models.
Mitew S; Kirkcaldie MT; Halliday GM; Shepherd CE; Vickers JC; Dickson TC
Acta Neuropathol; 2010 May; 119(5):567-77. PubMed ID: 20198482
[TBL] [Abstract][Full Text] [Related]
20. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
